Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT ID: NCT06799247
Last Updated: 2026-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
100 participants
INTERVENTIONAL
2025-05-06
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)
NCT04146051
Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis
NCT02609022
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
NCT03971422
A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
NCT06688435
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT00727194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Decartes-08
This group will undergo leukapheresis and receive manufactured Decartes-08
Decartes-08
Autologous mRNA CAR T-cell therapy
Placebo
This group will receive placebo
Placebo Drug
infusion without Decartes-08
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Decartes-08
Autologous mRNA CAR T-cell therapy
Placebo Drug
infusion without Decartes-08
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient must have generalized myasthenia gravis (gMG), Myasthenia Gravis Foundation of America (MGFA) clinical classification grades 2-4 at the time of Sscreening.
* MG-Activities of Daily Living (MG ADL) total score ≥ 6.
* Concomitant immunosuppressive drugs must be deemed necessary by the investigator. The dose must be stable for a minimum of 8 weeks prior to Baseline visit.
* If a patient is using corticosteroids, the daily dose should not exceed 40 mg/day of prednisone equivalent. The dose must have been stable for a minimum of 8 weeks prior to Baseline visit.
* Acetylcholine receptor autoantibody (anti-nAChR) titer or anti-AChR cluster antibody must be above the reference laboratory upper normal limit (UNL) and documented within the past 10 years of screening.
* Patient must be willing to return for all study visits.
* Patient must be able to give written informed consent.
* Women of childbearing potential must agree to use highly effective birth control from Screening until 14 days post last dose of Descartes-08,
Exclusion Criteria
* Diagnosis of gMG within 12 months of screening.
* No history of systemic treatment for gMG other than acetylcholine esterase inhibitors.
* Diagnosis of a neuromuscular disease other than gMG.
* Patient is pregnant or lactating.
* Treatment with intravenous immunoglobulin (IVIG) or plasma exchange within 4 weeks prior to the Baseline visit.
* Treatment with rituximab or ocrelizumab within 12 months prior to Baseline visit; treatment with calcineurin inhibitors (e.g. tacrolimus, cyclosporine, cyclophosphamide), Neonatal Fc receptor antagonists, and/or other biologics within 3 weeks prior to planned leukapheresis and within 8 weeks prior to Baseline visit.
* The patient has started treatment with a complement 5a (C5a) inhibitor, such as eculizumab, within 8 weeks of Baseline visit. (NOTE: patients who have been receiving a C5a inhibitor for more than 8 weeks and meet other criteria for enrollment are eligible for treatment).
* Prior treatment with B-cell maturation antigen (BCMA)-directed therapy (e.g. monoclonal antibody, T-cell engager, or chimeric antigen receptor T-cell \[CAR-T\]).
* Abnormal prothrombin (PT)/international normalized ratio (INR) or partial thromboplastin time (PTT) increased \> 1.5-fold above the normal range at Screening or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant; or in patients who have been on stable doses of anticoagulation therapy for more than 6 months of venous thromboembolism (VTE) diagnosis; or in patients on stable doses of anticoagulation therapy for at least 8 weeks of atrial fibrillation diagnosis; these conditions will not be exclusionary unless, in the investigator's opinion, they make participation in the study unsafe).
* Absolute neutrophil count (ANC) \< 1000 cells/microliter.
* Hemoglobin \< 8.0 g/dL.
* Platelets \< 50,000/mm3.
* Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 3x above normal.
* Creatine clearance less than 30 mL/min.
* History of primary immunodeficiency, organ, or allogeneic bone marrow transplant.
* Patients must be seronegative for hepatitis B surface antigen.
* Patients must be seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patients must be tested for the presence of viremia by reverse transcriptase polymerase chain reaction (RT-PCR) and must be hepatitis C virus (HCV) ribonucleic acid (RNA) negative.
* History of positive human immunodeficiency virus (HIV) or positive HIV at screening.
* Active tuberculosis or positive QuantiFERON test at screening.
* Any other clinical or laboratory abnormality that, in the opinion of the investigator, may jeopardize the subject's ability to participate in the study or could affect study outcome.
* Any active significant cardiac or pulmonary disease that, in the opinion of the Principal Investigator, is significant and/or uncontrolled.
Note: Patients with asthma and chronic obstructive pulmonary disease (COPD) controlled with inhaled medications are allowed.
* History of malignancy that required treatment in the past 3 years, except for squamous cell carcinoma, basal cell carcinoma of the skin, or breast or early-stage colon cancer that is surgically removed and did not require adjuvant chemotherapy or radiotherapy.
* Treatment with any investigational agent 4 weeks prior to screening or 5 half-lives of the investigational drug (whichever is longer).
* Receipt of a live vaccination within 4 weeks prior to Baseline visit or intent to receive live vaccination during the study (Note: messenger RNA \[mRNA\]-based vaccines such as those against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are not considered live; likewise, the Janssen Covid-19 vaccine is not live).
* History of significant recurrent infections or any active infection that in the opinion of the Investigator may interfere with the patient's participation in the opinion of the investigator.
* Any known psychiatric illness that in the opinion of the Investigator, may interfere with the patient's participation in the study in the opinion of the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cartesian Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A40
Tucson, Arizona, United States
A13
Carlsbad, California, United States
A14
Orange, California, United States
A21
Aurora, Colorado, United States
A48
Maitland, Florida, United States
A10
Tampa, Florida, United States
A53
O'Fallon, Illinois, United States
A20
Fairway, Kansas, United States
A38
Boston, Massachusetts, United States
A12
Amherst, New York, United States
A47
New York, New York, United States
A22
Chapel Hill, North Carolina, United States
A43
Houston, Texas, United States
A41
Seattle, Washington, United States
A23
Rome, , Italy
A30
Krakow, , Poland
A24
Belgrade, , Serbia
A25
Barcelona, , Spain
A31
Madrid, , Spain
A32
Ankara, , Turkey (Türkiye)
A17
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RNAC-MG-002 (AURORA)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.